• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脊髓小脑性共济失调 1、2、3、6 型患者的生存情况(EUROSCA):一项纵向队列研究。

Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study.

机构信息

Institut Pierre Louis d'Epidémiologie et de Santé Publique IPLESP, Sorbonne Université, INSERM, Paris, France.

Department of Neurology, University Hospital of Heidelberg, Heidelberg, Germany; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

出版信息

Lancet Neurol. 2018 Apr;17(4):327-334. doi: 10.1016/S1474-4422(18)30042-5. Epub 2018 Mar 13.

DOI:10.1016/S1474-4422(18)30042-5
PMID:29553382
Abstract

BACKGROUND

Spinocerebellar ataxias are dominantly inherited progressive ataxia disorders that can lead to premature death. We aimed to study the overall survival of patients with the most common spinocerebellar ataxias (SCA1, SCA2, SCA3, and SCA6) and to identify the strongest contributing predictors that affect survival.

METHODS

In this longitudinal cohort study (EUROSCA), we enrolled men and women, aged 18 years or older, from 17 ataxia referral centres in ten European countries; participants had positive genetic test results for SCA1, SCA2, SCA3, or SCA6 and progressive, otherwise unexplained, ataxias. Survival was defined as the time from enrolment to death for any reason. We used the Cox regression model adjusted for age at baseline to analyse survival. We used prognostic factors with a p value less than 0·05 from a multivariate model to build nomograms and assessed their performance based on discrimination and calibration. The EUROSCA study is registered with ClinicalTrials.gov, number NCT02440763.

FINDINGS

Between July 1, 2005, and Aug 31, 2006, 525 patients with SCA1 (n=117), SCA2 (n=162), SCA3 (n=139), or SCA6 (n=107) were enrolled and followed up. The 10-year survival rate was 57% (95% CI 47-69) for SCA1, 74% (67-81) for SCA2, 73% (65-82) for SCA3, and 87% (80-94) for SCA6. Factors associated with shorter survival were: dysphagia (hazard ratio 4·52, 95% CI 1·83-11·15) and a higher value for the Scale for the Assessment and Rating of Ataxia (SARA) score (1·26, 1·19-1·33) for patients with SCA1; older age at inclusion (1·04, 1·01-1·08), longer CAG repeat length (1·16, 1·03-1·31), and higher SARA score (1·15, 1·10-1·20) for patients with SCA2; older age at inclusion (1·44, 1·20-1·74), dystonia (2·65, 1·21-5·53), higher SARA score (1·26, 1·17-1·35), and negative interaction between CAG and age at inclusion (0·994, 0·991-0·997) for patients with SCA3; and higher SARA score (1·17, 1·08-1·27) for patients with SCA6. The nomogram-predicted probability of 10-year survival showed good discrimination (c index 0·905 [SD 0·027] for SCA1, 0·822 [0·032] for SCA2, 0·891 [0·021] for SCA3, and 0·825 [0·054] for SCA6).

INTERPRETATION

Our study provides quantitative data on the survival of patients with the most common spinocerebellar ataxias, based on a long follow-up period. These results have implications for the design of future interventional studies of spinocerebellar ataxias; for example, the prognostic survival nomogram could be useful for selection and stratification of patients. Our findings need validation in an external population before they can be used to counsel patients and their families.

FUNDING

European Union 6th Framework programme, German Ministry of Education and Research, Polish Ministry of Scientific Research and Information Technology, European Union 7th Framework programme, and Fondation pour la Recherche Médicale.

摘要

背景

脊髓小脑共济失调是一种显性遗传性进行性共济失调疾病,可导致过早死亡。我们旨在研究最常见的脊髓小脑共济失调(SCA1、SCA2、SCA3 和 SCA6)患者的总体生存率,并确定影响生存的最强预测因素。

方法

在这项欧洲脊髓小脑共济失调研究(EUROSCA)中,我们招募了来自 10 个欧洲国家的 17 个共济失调转诊中心的 18 岁及以上的男性和女性;参与者具有 SCA1、SCA2、SCA3 或 SCA6 的阳性基因检测结果和进行性、其他原因不明的共济失调。生存定义为从入组到任何原因死亡的时间。我们使用 Cox 回归模型调整了基线时的年龄来分析生存。我们使用多变量模型中 p 值小于 0.05 的预后因素来构建列线图,并根据区分度和校准度评估其性能。EUROSCA 研究在 ClinicalTrials.gov 上注册,编号为 NCT02440763。

发现

在 2005 年 7 月 1 日至 2006 年 8 月 31 日期间,我们招募了 525 名 SCA1(n=117)、SCA2(n=162)、SCA3(n=139)或 SCA6(n=107)患者,并进行了随访。SCA1 的 10 年生存率为 57%(95%CI 47-69),SCA2 为 74%(67-81),SCA3 为 73%(65-82),SCA6 为 87%(80-94)。与生存率较短相关的因素包括:吞咽困难(危险比 4.52,95%CI 1.83-11.15)和 SCA1 患者的共济失调评估和评分量表(SARA)评分较高(1.26,1.19-1.33);年龄较大(1.04,1.01-1.08)、CAG 重复长度较长(1.16,1.03-1.31)和 SARA 评分较高(1.15,1.10-1.20);年龄较大(1.44,1.20-1.74)、肌张力障碍(2.65,1.21-5.53)、SARA 评分较高(1.26,1.17-1.35)和 CAG 与年龄的负交互作用(0.994,0.991-0.997);SCA3 患者 SARA 评分较高(1.17,1.08-1.27)。列线图预测的 10 年生存率显示出良好的区分度(SCA1 的 c 指数为 0.905 [0.027],SCA2 为 0.822 [0.032],SCA3 为 0.891 [0.021],SCA6 为 0.825 [0.054])。

解释

我们的研究提供了基于长期随访的最常见脊髓小脑共济失调患者生存的定量数据。这些结果对脊髓小脑共济失调的未来干预研究设计具有重要意义;例如,预后生存列线图可用于选择和分层患者。在将其用于指导患者及其家属之前,我们需要在外部人群中验证这些发现。

资金

欧盟第六框架计划、德国教育和研究部、波兰科学研究和信息技术部、欧盟第七框架计划以及法国医学研究基金会。

相似文献

1
Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study.脊髓小脑性共济失调 1、2、3、6 型患者的生存情况(EUROSCA):一项纵向队列研究。
Lancet Neurol. 2018 Apr;17(4):327-334. doi: 10.1016/S1474-4422(18)30042-5. Epub 2018 Mar 13.
2
Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study.脊髓小脑性共济失调 1、2、3、6 型的长期疾病进展:一项纵向队列研究。
Lancet Neurol. 2015 Nov;14(11):1101-8. doi: 10.1016/S1474-4422(15)00202-1. Epub 2015 Sep 13.
3
Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study.将脊髓小脑共济失调 1、2、3、6 型的风险个体转化为显性共济失调(RISCA):一项纵向队列研究。
Lancet Neurol. 2020 Sep;19(9):738-747. doi: 10.1016/S1474-4422(20)30235-0.
4
Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data.在 RISCA 纵向研究中,脊髓小脑共济失调 1、2、3 和 6 型风险个体的生物学和临床特征:基线数据分析。
Lancet Neurol. 2013 Jul;12(7):650-8. doi: 10.1016/S1474-4422(13)70104-2. Epub 2013 May 22.
5
Long-term evolution of patient-reported outcome measures in spinocerebellar ataxias.脊髓小脑共济失调患者报告结局测量的长期演变。
J Neurol. 2018 Sep;265(9):2040-2051. doi: 10.1007/s00415-018-8954-0. Epub 2018 Jun 29.
6
Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms.脊髓小脑共济失调1型、2型、3型和6型:疾病严重程度及非共济失调症状
Neurology. 2008 Sep 23;71(13):982-9. doi: 10.1212/01.wnl.0000325057.33666.72. Epub 2008 Aug 6.
7
The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study.1型、2型、3型和6型脊髓小脑共济失调的自然病史:一项为期2年的随访研究。
Neurology. 2011 Sep 13;77(11):1035-41. doi: 10.1212/WNL.0b013e31822e7ca0. Epub 2011 Aug 10.
8
Disease progression of spinocerebellar ataxia types 1, 2, 3 and 6 before and after ataxia onset.脊髓小脑共济失调 1、2、3 和 6 型在共济失调发作前后的疾病进展。
Ann Clin Transl Neurol. 2023 Oct;10(10):1833-1843. doi: 10.1002/acn3.51875. Epub 2023 Aug 17.
9
Natural history of most common spinocerebellar ataxia: a systematic review and meta-analysis.最常见的脊髓小脑共济失调的自然史:系统评价和荟萃分析。
J Neurol. 2021 Aug;268(8):2749-2756. doi: 10.1007/s00415-020-09815-2. Epub 2020 Apr 7.
10
Dystonia and ataxia progression in spinocerebellar ataxias.脊髓小脑共济失调的肌张力障碍和共济失调进展。
Parkinsonism Relat Disord. 2017 Dec;45:75-80. doi: 10.1016/j.parkreldis.2017.10.007. Epub 2017 Oct 23.

引用本文的文献

1
Content Validity of the Spinocerebellar Ataxia Composite Score as a Measure of Disease Progression in Patients with Spinocerebellar Ataxia.脊髓小脑共济失调综合评分作为脊髓小脑共济失调患者疾病进展指标的内容效度
Cerebellum. 2025 Sep 1;24(5):146. doi: 10.1007/s12311-025-01896-x.
2
Longitudinal description of health-related quality of life and depressive symptoms in polyQ spinocerebellar ataxia patients.多聚谷氨酰胺脊髓小脑共济失调患者健康相关生活质量和抑郁症状的纵向描述
J Neurol. 2025 Apr 9;272(5):323. doi: 10.1007/s00415-025-13024-0.
3
Sex Differences in a Novel Mouse Model of Spinocerebellar Ataxia Type 1 (SCA1).
1型脊髓小脑共济失调(SCA1)新型小鼠模型中的性别差异。
Int J Mol Sci. 2025 Mar 14;26(6):2623. doi: 10.3390/ijms26062623.
4
Depression and Associated Factors Among Patients with Spinocerebellar Ataxia.脊髓小脑共济失调患者的抑郁及相关因素
Medicina (Kaunas). 2025 Jan 19;61(1):160. doi: 10.3390/medicina61010160.
5
Content Validity of the Friedreich Ataxia Rating Scale in Patients with Spinocerebellar Ataxia.脊髓小脑共济失调患者中Friedreich共济失调评定量表的内容效度
Neurol Ther. 2025 Apr;14(2):547-563. doi: 10.1007/s40120-024-00704-8. Epub 2025 Jan 15.
6
Measurement Properties of the Friedreich Ataxia Rating Scale in Patients with Spinocerebellar Ataxia.脊髓小脑共济失调患者中弗里德赖希共济失调评定量表的测量属性
Neurol Ther. 2025 Apr;14(2):527-545. doi: 10.1007/s40120-024-00708-4. Epub 2025 Jan 13.
7
Subtypes of cognitive impairment in cerebellar disease identified by cross-diagnostic cluster-analysis: results from a German multicenter study.通过交叉诊断聚类分析确定的小脑疾病认知障碍亚型:一项德国多中心研究的结果
J Neurol. 2024 Dec 21;272(1):83. doi: 10.1007/s00415-024-12831-1.
8
Differences in the Impact of Intensive Rehabilitation on Hereditary Ataxias and the Cerebellar Subtype of Multiple System Atrophy.遗传性共济失调与多系统萎缩小脑型强化康复治疗影响的差异。
Cerebellum. 2024 Dec;23(6):2447-2456. doi: 10.1007/s12311-024-01744-4. Epub 2024 Oct 4.
9
Increased frequency of repeat expansion mutations across different populations.在不同人群中,重复扩展突变的频率增加。
Nat Med. 2024 Nov;30(11):3357-3368. doi: 10.1038/s41591-024-03190-5. Epub 2024 Oct 1.
10
Spinocerebellar Ataxia in Brazil: A Comprehensive Genotype - Phenotype Analysis.巴西脊髓小脑共济失调:全面的基因型-表型分析。
Cerebellum. 2024 Dec;23(6):2414-2425. doi: 10.1007/s12311-024-01745-3. Epub 2024 Sep 25.